Abstract
The field of metal-based anticancer drugs was initiated by cisplatin, one of the leading agents in clinical use. Cisplatin acts by binding to DNA and forming 1,2 intrastrand cross-links. Its importance is reflected by the fact that it is estimated that 50-70 % of cancer patients are treated with a platinum drug [7]. For some time, molecular designs in the metallo-drug field remained obdurately anchored in cis-diamine platinum(II) chemistry, but now the field is evolving rapidly with a variety of alternate and very diverse designs being explored. These designs give rise to new spectra of activity and potency and can circumvent cisplatin resistance. This critical review considers the existing clinical platinum drugs, and those currently in commercial development, alongside the new designs including ruthenium anticancer and antimetastatic drugs in clinical trials, polynuclear drugs, organometallic drugs, titanium and gallium drugs, and emerging supramolecular metallo-drugs that act on DNA by noncovalent interactions. The rapid evolution of the field is being informed by post-genomic knowledge and approaches, and further dramatic step-change breakthroughs can be expected as a result; harnessing this knowledge and responding to and taking advantage of this new environment requires integration of chemistry and biology research.
References
1. (a) doi:10.1002/(SICI)1521-3773(19990601)38:11<1512::AID-ANIE1512>3.0.CO;2-Y, Z. Guo, P. J. Sadler. Angew. Chem., Int. Ed. 38, 1512 (1999);Search in Google Scholar
1. (b) doi:10.1039/b514859f, T. Storr, K. H. Thompson, C. Orvig. Chem. Soc. Rev. 35, 534 (2006).Search in Google Scholar
2. B. Lippert (Ed.). Cisplatin, Chemistry and Biochemistry of a Leading Anticancer Drug, Wiley-VCH, Weinheim (1999).10.1002/9783906390420Search in Google Scholar
3. doi:10.1039/cc9960000801, J. Reedijk. Chem. Commun. 801 (1996).Search in Google Scholar
4. Z. J. Guo, P. J. Sadler. Adv. Inorg. Chem. 49, 183 (2000).10.1016/S0898-8838(08)60271-8Search in Google Scholar
5. doi:10.1016/S0162-0134(99)00147-6, J. D. Roberts, J. Peroutka, N. Farrell. J. Inorg. Biochem. 77, 51 (1999).Search in Google Scholar
6. S. J. Lippard, J. M. Berg. Principles of Bioinorganic Chemistry, University Science Books, Mill Valley, CA (1994).Search in Google Scholar
7. doi:10.1039/b601840h, P. J. Dyson, G. Sava. Dalton Trans. 1929 (2006).Search in Google Scholar
8. B. Rosenberg. In Cisplatin, Chemistry and Biochemistry of a Leading Anticancer Drug, B.Lippert (Ed.), Wiley-VCH, Weinheim (1999).Search in Google Scholar
9. doi:10.1038/377649a0, P. M. Takahara, A. C.Rosenzweig,C. A.Frederick,S. J.Lippard. Nature 377, 649 (1995).Search in Google Scholar
10. doi:10.1038/21460, U. M. Ohndorf, M. A.Rould, Q.He, C. O.Pabo, S. J. Lippard. Nature 399, 708 (1999).Search in Google Scholar
11. doi:10.1039/b606046n, M. J. Hannon. Chem. Soc. Rev. 36, 280 (2007).Search in Google Scholar
12. doi:10.1016/S0006-3061(00)80249-5, M. J. Cleare, J. D. Hoeschele. Bioinorg. Chem. 2, 187 (1973).Search in Google Scholar
13. (a) For details on Satraplatin development, see <http://www.gpc-biotech.com/en/anticancer_programs/satraplatin/index.html>: <http://investor.pharmion.com/phoenix.zhtml?c=142045&p=irol-newsArticle&ID=1010774&highlight>;Search in Google Scholar
13. (b) For details on Miriplatin development, see <http://www.ds-pharma.co.jp/english/news/pdf/ne20060724.pdf>;Search in Google Scholar
13. (c) For details on ProLindac development, see <http://www.accesspharma.com/pr/070416.PDF>;Search in Google Scholar
13. (d) For details on BP-C1 development, see <http://www.meabco.com/RD%20BP-C1%20BC.htm>;Search in Google Scholar
13. (e) For details on cisplatin Lipid Complex development, see <http://www.transaveinc.com/products.shtml>;Search in Google Scholar
13. (f) For details on Aroplatin development, see <http://www.antigenics.com/products/cancer/aroplatin/>;Search in Google Scholar
13. (g) For details on Picoplatin development, see <http://www.poniard.com/> or <http://investor.poniard.com/ReleaseDetail.cfm?ReleaseID=246847>, which provides outline information on Picoplatin Phase II and III trials;Search in Google Scholar
13. (h) For other recent reviews, see L. R. Kelland. Nat. Rev. Cancer 7, 573 (2007);10.1038/nrc2167Search in Google Scholar
13. (i) doi:10.1021/jm070280u, M. D. Hall, H. R. Mellor, R. Callaghan, T. W. Hambley. J. Med. Chem. 50, 3403 (2007).Search in Google Scholar
14. (a) doi:10.1038/sj.bjc.6600854, P. Beale, I. Judson, A. O'Donnell. Br. J. Cancer 88, 1128 (2003);Search in Google Scholar
14. (b) J. Holford, S. Y. Sharp, B. A. Murrer, M. Abrams, L. R. Kelland. Br. J. Cancer 77, 366 (1998).10.1038/bjc.1998.59Search in Google Scholar
15. doi:10.1007/s00280-006-0235-4, T. Dragovich, D. Mendelson, S. Kurtin, K. Richardson, D. Von Hoff, A. Hoos. Cancer Chemother. Pharmacol. 58, 759 (2006).Search in Google Scholar
16. G. P. Stathopoulos, T. Boulikas, M. Vougiouka, G. Deliconstantinos, S. Rigatos, E. Darli, V.Viliotoy, J. G. Stathopoulos. Oncol. Rep. 13, 589 (2005).Search in Google Scholar
17. B. Rosenberg, L. Van Camp, E. B. Grimley, A. J. Thomson. J. Biol. Chem. 242, 1347 (1967).10.1016/S0021-9258(18)96186-7Search in Google Scholar
18. doi:10.1016/S0010-8545(01)00315-0, G. Natile, M. Coluccia. Coord. Chem. Rev. 216-217, 383 (2001).Search in Google Scholar
19. doi:10.1021/jm00130a002, N. Farrell, T. T. B. Ha, J.-P. Souchard, F. L. Wimmer, S. Cros, N. P. Johnson. J. Med. Chem. 32, 2240 (1989).Search in Google Scholar
20. doi:10.1021/jm991015e, E. I. Montero, S. Diaz, A. M. Gonzalez-Vadillo, J. M. Perez, C. Alonso, C. Navarro-Ranninger. J. Med. Chem. 42, 4264 (1999).Search in Google Scholar
21. doi:10.1021/jm00056a012, M. Coluccia, A. Nassi, F. Loseto, A. Boccarelli, M. A. Mariggio, D. Giordano, F. P. Intini, P. A. Caputo, G. Natile. J. Med. Chem. 36, 510 (1993).Search in Google Scholar
22. N. Farrell. Metal Ions Biol. Sys. 41, 252 (2004).Search in Google Scholar
23. doi:10.1021/bi991202e, M. B. Kloster, J. C. Hannis, D. C. Muddiman, N. Farrell. Biochemistry 38, 14731 (1999).Search in Google Scholar
24. doi:10.1016/j.ejca.2004.04.032, D. Jodrell, T. Evans, W. Steward, D. Cameron, J. Prendiville, C. Aschele, C. Noberasco, M. Lind, J. Carmichael, N. Dobbs. Eur. J. Cancer 40, 1872 (2004).Search in Google Scholar
25. (a) doi:10.2174/1568026043387421, E. Alessio, G. Mestroni, A. Bergamo, G. Sava. Curr. Top. Med. Chem. 4, 1525 (2004);Search in Google Scholar
25. (b) E.Alessio, G. Mestroni, A. Bergamo, G. Sava. Metal Ions Biol. Sys. 42, 323 (2004).10.1201/b12414-10Search in Google Scholar
26. doi:10.1016/j.jinorgbio.2006.02.013, C. G. Hartinger, S. Zorbas-Selfried, M. A. Jakupee, B. Kynast, H. Zorbas, B. K. Keppler. J. Inorg. Biochem. 100, 891 (2006).Search in Google Scholar
27. doi:10.1039/b508531b, Y. K. Yan, M. Melchart, A. Habtemariam, P. J. Sadler. Chem. Commun. 4764 (2005).Search in Google Scholar
28. doi:10.1016/j.drup.2006.05.002, V. Brabec, O. Novakova. Drug Resist. Updates 9, 111 (2006).Search in Google Scholar
29. doi:10.1016/j.chembiol.2004.11.008, O. Novakova, J. Kasparkova, V. Bursova, C. Hofr, M. Vojtiskova, H. Chen, P. J. Sadler, V. Brabec. Chem. Biol. 12, 121 (2005).Search in Google Scholar
30. doi:10.1002/ejic.200600723, W. H. Ang, P. J. Dyson. Eur. J. Inorg. Chem. 4003 (2006).Search in Google Scholar
31. G. Jaouen (Ed.). Bioorganometallics: Biomolecules, Labelling, Medicine, Wiley-VCH, Weinheim (2005).10.1002/3527607692Search in Google Scholar
32. doi:10.1039/b509984f, A. Vessieres, S. Top, W. Beck, E. Hillard, G. Jaouen. Dalton Trans. 529 (2006).Search in Google Scholar
33. C. Boit. Curr. Med. Chem. Anti-Infect. Agents 3, 135 (2004).10.2174/1568012043354008Search in Google Scholar
34. M. M. Harding, G. Mokdsi. Curr. Med. Chem. 7, 1289 (2000).10.2174/0929867003374066Search in Google Scholar
35. doi:10.1097/CAD.0b013e3280115f86, O. Oberschmidt, A. R. Hanauske, C. Pampillon, N. J. Sweeney, K. Strohfeldt, M. Tacke. Anticancer Drugs 18, 317 (2007).Search in Google Scholar
36. (a) doi:10.1021/om030403i, O. R. Allen, L. Croll, A. L. Gott, R. J. Knox, P. C. McGowan. Organometallics 23, 288 (2004);Search in Google Scholar
36. (b) doi:10.1016/j.inoche.2006.07.019, G. D. Potter, M. C. Baird, M. Chan, S. P. Cole. Inorg. Chem. Commun. 9, 1114 (2006).Search in Google Scholar
37. (a) doi:10.1016/j.jinorgbio.2006.07.003, A. V. Rudnev, L. S. Foteeva, C. Kowol, R. Berger, M. A. Jakupec, V. B. Arion, A. R. Timerbaev, B. K. Keppler. J. Inorg. Biochem. 100, 1819 (2006);Search in Google Scholar
37. (b) doi:10.2174/1568026043387449, M. A. Jakupec, B. K. Keppler. Curr. Top. Med. Chem. 4, 1575 (2004).Search in Google Scholar
38. R. Martinez, L. Chacon-Garcia. Curr. Med. Chem. 12, 127 (2005).10.2174/0929867053363414Search in Google Scholar
39. doi:10.1002/med.20000, P. G. Baraldi, A. Bovero, F. Fruttarolo, D. Preti, M. A. Tabrizi, M. G. Pavani, R. Romagnoli. Med. Res. Rev. 24, 475 (2004).Search in Google Scholar
40. doi:10.1021/bi00462a016, C. A. Frederick, L. D.Williams, G.Ughetto, G. A.van der Marel, J. H.van Boom, A.Rich, A.H.Wang. Biochemistry 29, 2538 (1990).Search in Google Scholar
41. doi:10.1016/j.inoche.2005.10.016, F. Pierard, A. Kirsch-De Mesmaeker. Inorg. Chem. Commun. 9, 111 (2006).Search in Google Scholar
42. doi:10.1021/ja003624d, B. Onfelt, P. Lincoln, B. Norden. J. Am. Chem. Soc. 123, 3630 (2001).Search in Google Scholar
43. P. Lincoln, B. Norden. PCT/SE98/01655, (1998). The agent is not active in some other cell lines: B. Onfelt, L. Gostring, P. Lincoln, B. Norden, A. Onfelt. Mutagenesis 17, 317 (2002).Search in Google Scholar
44. doi:10.1002/ejic.200500110, A. C. G. Hotze, E. P. L. van der Geer, H. Kooijman, A. L. Spek, J. G. Haasnoot, J. Reedijk. Eur. J. Inorg. Chem. 2648 (2005).Search in Google Scholar
45. doi:10.1248/cpb.52.178, U. K. Mazumder, M. Gupta, S. S. Karki, S. Bhattacharya, S. Rathinasamy, S. Thangavel. Chem. Pharm. Bull. 52, 178 (2004).Search in Google Scholar
46. (a) M. J. Hannon, V. Moreno, M. J. Prieto, E. Moldrheim, E. Sletten, I. Meistermann, C. J. Isaac, K. J. Sanders, A. Rodger. Angew. Chem., Int. Ed. 40, 880 (2001);10.1002/1521-3773(20010302)40:5<879::AID-ANIE879>3.0.CO;2-XSearch in Google Scholar
46. (b) doi:10.1073/pnas.062634499, I. Meistermann, V. Moreno, M. J. Prieto, E. Moldrheim, E. Sletten, S. Khalid, M. Rodger, J. Peberdy, C. J. Isaac, A. Rodger, M. J. Hannon. Proc. Natl. Acad. Sci. USA 99, 5069 (2002);Search in Google Scholar
46. (c) doi:10.1002/chem.200600060, L. J. Childs, J. Malina, B. E. Rolfsnes, M. Pascu, M. J. Prieto, M. J. Broome, P. M. Rodger, E. Sletten, V. Moreno, A. Rodger, M. J. Hannon. Chem.Eur. J. 12, 4919 (2006);Search in Google Scholar
46. (d) doi:10.1002/chem.200401054, C. Uerpmann, J. Malina, M. Pascu, G. J. Clarkson, V. Moreno, A. Rodger, A. Grandas, M. J. Hannon. Chem.Eur. J. 11, 1750 (2005);Search in Google Scholar
46. (e) doi:10.1002/chem.200501168, S. Khalid, M. J. Hannon, A. Rodger, P. M. Rodger.Chem.Eur. J. 12, 3493 (2006).Search in Google Scholar
47. doi:10.1002/anie.200503822, A. Oleksi, A. G. Blanco, R. Boer, I. Uson, J. Aymami, A. Rodger, M. J. Hannon,M. Coll. Angew. Chem., Int. Ed. 45, 1227 (2006).Search in Google Scholar
48. doi:10.1021/ic062415c, L. Cerasino, M. J. Hannon, E. Sletten. Inorg. Chem. 46, 6245 (2007).Search in Google Scholar
49. doi:10.1002/chem.200700159, J. Malina, M. J. Hannon, V. Brabec. Chem.Eur. J. 14, 3871 (2007).Search in Google Scholar
50. (a) doi:10.1002/anie.200700656, G. I. Pascu, A. C. G. Hotze, C. Sanchez Cano, B. M. Kariuki, M. J. Hannon. Angew. Chem., Int. Ed. 46, 4374 (2007);Search in Google Scholar
50. (b) M. J. Hannon, A. Rodger, N. H. Mann. PCT/GB2004/004227 (2004).Search in Google Scholar
51. doi:10.1002/anie.200601351, A. C. G. Hotze, B. M. Kariuki, M. J. Hannon. Angew. Chem., Int. Ed. 45, 4839 (2006).Search in Google Scholar
52. (a) doi:10.1007/s00775-004-0531-6, A. C. G. Hotze, S. E. Caspers, D. de Vos, H. Kooijman, A. L. Spek, A. Flamigni, M. Bacac, G. Sava, J. G. Haasnoot, J. Reedijk. J. Biol. Inorg. Chem. 9, 354 (2004);Search in Google Scholar
52. (b) doi:10.1039/b313182c, A. H. Velders, K. van der Schilden, A. C. G. Hotze, J. Reedijk, H. Kooijman, A. L. Spek. Dalton Trans. 448 (2004).Search in Google Scholar
53. doi:10.1021/ja062851y, S. Komeda, T. Moulaei, K. K. Woods, M. Chikuma, N. P. Farrell, L. D. Williams. J. Am. Chem. Soc. 128, 16092 (2006).Search in Google Scholar
54. (a) doi:10.1021/ic051390z, A. L. Harris, X. H. Yang, A. Hegmans, L. Povirk, J. J. Ryan, L. Kelland, N. P. Farrell. Inorg. Chem. 44, 9598 (2005);Search in Google Scholar
54. (b) A. L. Harris, J. J. Ryan, N. Farrell. Mol. Pharm. 69, 666 (2006).Search in Google Scholar
55. (a) See, for example, S. Top, E. B. Kaloun, A. Vessieres, G. Leclercq, I. Laios, M. Ourevitch, C.Deuschel, M. J. McGlinchey, G. Jaouen. ChemBioChem 4, 754 (2003);10.1002/cbic.200200550Search in Google Scholar PubMed
55. (b) doi:10.1002/chem.200501012, M. J. Hannon, P. S. Green, D. M. Fisher, P. J. Derrick, J. L. Beck, S. J. Watt, M. M. Sheil, P. R. Barker, N. W. Alcock, R. J. Price, K. J. Sanders, R. Pither, J. Davis, A. Rodger. Chem.Eur. J. 12, 8000 (2006);Search in Google Scholar
55. (c) doi:10.1016/j.chembiol.2004.03.024, K.R.Barnes, A. Kutikov, S. J. Lippard. Chem. Biol. 11, 557 (2004);Search in Google Scholar
55. (d) doi:10.1016/j.bioorg.2004.06.009, V. Perron, D. Rabouin, E. Asselin, S. Parent, R. C. Gaudreault, G. Berube. Bioorg. Chem. 33, 1 (2005);Search in Google Scholar
55. (e) M. Galanski, B. K. Keppler. Anticancer Agents Med. Chem. 7, 55 (2007);10.2174/187152007779314017Search in Google Scholar PubMed
55. (f) doi:10.1039/b513476e, K. H. Thompson, C. Orvig. Dalton Trans. 761 (2006).Search in Google Scholar
56. See, for example, L. J. Childs, M. J. Hannon. Supramol. Chem. 16, 7 (2004).10.1080/10610270310001632386Search in Google Scholar
© 2013 Walter de Gruyter GmbH, Berlin/Boston
